Anzeige
Meldung des Tages: Antimon wieder im Fokus: ATMY erreicht Allzeithoch – Verteidigungsnachfrage treibt den Markt

VolitionRX News

Aktie
WKN:  A12B6K ISIN:  US9286611077 US-Symbol:  VNRX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,1401 $
-0,0039 $
-2,71%
0,11955 € 24.04.26
Depot/Watchlist
Marktkapitalisierung *
22,85 Mio. €
Streubesitz
62,90%
KGV
-1,94
Index-Zuordnung
-

VolitionRX News

23.04.26 - PR Newswire
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire
20.04.26 - PR Newswire
Volition Launches rNuQ™ Webshop Broadening Product Range
Volition Launches rNuQ™ Webshop Broadening Product Range PR Newswire
31.03.26 - PR Newswire
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire
31.03.26 - PR Newswire
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
VolitionRx Secures EUR 2.0 Million of Non-​Dilutive Funding from Regional Government Agencies in Belgium PR Newswire
30.03.26 - PR Newswire
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients PR Newswire
26.03.26 - PR Newswire
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference PR Newswire
25.03.26 - PR Newswire
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR Newswire
25.03.26 - PR Newswire
Volition Announces Detection of Over 95% of Early-Stage Cancers
Volition Announces Detection of Over 95% of Early-​Stage Cancers PR Newswire
18.03.26 - PR Newswire
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA PR Newswire
06.03.26 - PR Newswire
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems PR Newswire
25.02.26 - PR Newswire
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
VolitionRx Highlights Commercial Momentum and Multi-​Pillar Execution PR Newswire
10.02.26 - PR Newswire
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
Volition Announces the Appointment of New Distributor for Nu.Q® Discover PR Newswire
09.02.26 - PR Newswire
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
VolitionRx Receives Notice of Non-​Compliance with NYSE American Continued Listing Standards PR Newswire
04.02.26 - PR Newswire
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation PR Newswire
30.01.26 - PR Newswire
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays PR Newswire
27.01.26 - PR Newswire
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication PR Newswire
20.01.26 - PR Newswire
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test PR Newswire
16.01.26 - PR Newswire
Volition Sponsors Symposium at Veterinary Meeting and Expo
Volition Sponsors Symposium at Veterinary Meeting and Expo PR Newswire
08.01.26 - PR Newswire
VolitionRx Secures $2.0 Million in Funding
VolitionRx Secures $2.0 Million in Funding PR Newswire
08.01.26 - PR Newswire
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats PR Newswire

Newssuche

Videos

newspaper
20.04.26 +3,54%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »